Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on September 10, 2013. The registrant is a Delaware corporation headquartered in Rockville, Maryland, focused on developing neural stem cell therapies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of specific corporate events rather than a financial statement.
Material Changes and Events
- Regulation FD Disclosure (Item 7.01): Company representatives presented at the 15th Annual Rodman & Renshaw Healthcare Conference in New York City on September 10, 2013. Presentation slides are included as Exhibit 99.01.
- Clinical Trial Milestone (Item 8.01): The Company announced the treatment of the first patient in its Phase II trial using NSI-566 spinal cord-derived neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS). The procedure took place at Emory University Hospital in Atlanta, Georgia.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard disclaimer that the information is not deemed "filed" under Section 18 of the Exchange Act. The primary focus is the advancement of the ALS clinical trial.
Investor Verification Checklist
- Verify the clinical progress and safety data of the NSI-566 Phase II trial for ALS.
- Review the presentation slides (Exhibit 99.01) for any non-financial updates on the company's pipeline or strategy.
- Confirm the company's cash runway and funding status in subsequent filings, as this 8-K does not disclose liquidity.
- Note the discrepancy in the request metadata: the filing is for Neuralstem, Inc., not Palisade Bio, Inc.